SL-GD002

SL-GD002 is an **allogeneic gamma delta T cell therapy** being developed by **SLBio** for **pancreatic cancer**. The program is part of the company's gamma delta T-cell platform and is described as a non-genetically modified, off-the-shelf cell therapy intended to leverage the **immunomodulatory and tumor-targeting activity of γδ T cells** against an immunosuppressive solid tumor microenvironment. Publicly available company pipeline information indicates that no specific molecular target has been disclosed and that the program is currently in **preclinical** development.

Other names

allogeneic gamma delta T cell therapyallogeneic γδ T cell therapy